| Adverse event | Chronic | Mortality | Cost | Disutility | Treatment following TRAE |
|---|---|---|---|---|---|
| Oral corticosteroids (prednisolone) | |||||
| Reduced BMD | Yes | No | Yes (lifetime) | No | Oral corticosteroid |
| Cataracts | No | No | Yes (one-off) | Yes (one-off) | Oral corticosteroid |
| Diabetes | Yes | Yes | Yes (lifetime) | Yes (lifetime) | Oral corticosteroid |
| NSAIDs (ibuprofen) | |||||
| Abdominal pain | No | No | No | Yes (1 week) | Macrolide |
| Abdominal bleed | No | No | Yes (one-off) | Yes (4 weeks) | Macrolide |
| Renal impairment | Yes | Yes | Yes (lifetime) | Yes (lifetime) | Macrolide |
| Macrolides (azithromycin) | |||||
| Hearing impairment | No | No | Yes (one-off) | Yes (one-off) | None |
BMD, bone mineral density; NSAID, nonsteroidal anti-inflammatory drugs TRAE, treatment related adverse event
From: Appendix K, Health Economics
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.